MedTrace Logo

Effectiveness of Combined Anticoagulation and Antithrombotic Therapy vs Antithrombotic Therapy Alone After Lower Extremity Revascularization for Peripheral Arterial Disease

NCT04994223 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-05-03

No results posted yet for this study

Summary

EFFECTIVENESS OF COMBINED ANTICOAGULATION AND ANTITHROMBOTIC THERAPY VS ANTITHROMBOTIC THERAPY ALONE AFTER LOWER EXTREMITY REVASCULARIZATION FOR PERIPHERAL ARTERIAL DISEASE.

Conditions

  • Combined Anticoagulation and Antithrombotic Therapy
  • PAD - Peripheral Arterial Disease

Interventions

DRUG

Rivaroxaban 10 MG Oral Tablet [Xarelto]

rivaroxaban has shown improved results after revascularization for PAD in terms of limb survival

Sponsors & Collaborators

  • Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-02
Primary Completion
2022-12-30
Completion
2022-12-30

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04994223 on ClinicalTrials.gov